Horizon Discovery Group announced that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND) filing with the United States Food and Drug Administration.   This successful filing demonstrates that the cells and recombinant adeno-associated virus (rAAV) engineering technology used in Horizon’s generation have been assessed as safe from a regulatory perspective for the manufacture of biotherapeutics...